FTC Healthcare Antitrust: The Current Enforcement Landscape

Introduction

Healthcare antitrust enforcement in 2025-2026 presents a more nuanced picture than the simple narrative of "new administration, less enforcement" might suggest. While the current FTC has adopted a generally more permissive stance toward large-scale M&A in many sectors, healthcare-specific enforcement has maintained significant intensity in several key areas. For healthcare bankers advising on transactions, understanding the current enforcement landscape is essential for deal timeline planning, structure optimization, and risk assessment.

The FTC's healthcare enforcement in 2025-2026 has focused on three primary areas.

Device market concentration. The FTC blocked Edwards Lifesciences' proposed acquisition of JenaValve Technology, a transcatheter aortic valve replacement (TAVR) competitor. The challenge was based on traditional horizontal merger analysis: the combination would have reduced the TAVR market from four competitors to three, with Edwards (the market leader) absorbing a potential disruptor. This enforcement action signals that the FTC continues to scrutinize device deals where the acquirer is the market leader and the target is a meaningful competitive constraint, regardless of the broader political environment.

Innovation Market Theory

An antitrust theory under which the FTC challenges acquisitions not because they reduce competition in an existing product market but because they eliminate a future competitive threat. In healthcare, the FTC has applied this theory to block deals where the acquirer purchases a clinical-stage competitor whose pipeline product would eventually compete with the acquirer's approved product. The theory is particularly relevant in pharma and device, where the most valuable competitive assets are often in development rather than on market. The innovation market theory raises the antitrust bar for healthcare M&A because it means that acquiring a company with no current revenue and no approved products can still trigger an FTC challenge if the target's pipeline threatens the acquirer's market position.

PE serial acquisition scrutiny. The FTC has continued its focus on PE roll-up strategies, maintaining the Biden-era position that individual add-on acquisitions falling below HSR filing thresholds can cumulatively create anticompetitive market concentration. Healthcare services roll-ups in anesthesiology, emergency medicine, and dermatology have attracted particular attention.

Staffing and labor market effects. The abandoned Aya Healthcare/Cross Country deal (healthcare staffing) reflected FTC concern about labor market concentration, not just product market competition. The agencies are increasingly willing to challenge healthcare transactions on the theory that combining large employers in localized healthcare labor markets reduces wages and working conditions for healthcare workers.

Perhaps the most significant development for healthcare M&A practitioners is the expansion of state-level antitrust and transaction review authority. Over 20 states have enacted or are considering "mini-HSR" laws that require advance notice and approval for healthcare transactions, even those below the federal HSR filing threshold.

These state requirements vary significantly: some apply only to hospital mergers, others cover physician practice acquisitions, and still others target PE acquisitions of healthcare entities specifically. The result is a patchwork of state-level filing obligations that adds both timeline and cost to healthcare transactions, particularly multi-state PE roll-ups where a single add-on acquisition may trigger filing requirements in several states simultaneously.

For healthcare bankers, the takeaway is that antitrust analysis should be front-loaded in every transaction, not treated as a late-stage risk that might require deal modification. The combination of federal innovation market theory, PE-focused enforcement, and expanding state-level review creates a multi-layered antitrust landscape that directly affects deal certainty, timeline, and structure.

The next article examines healthcare capital markets in 2026 and the state of the biotech IPO market.